Ireland
--:--IST
Latest
Astellas Expands Its 330 Million Euro Tralee Biopharma Facility with a Second Aseptic Filling Line to Double Drug-Product Capacity Xeolas Pharmaceuticals Opens 158,000 Sq Ft State-of-the-Art Baldoyle Facility to Scale Specialty Medicine Manufacturing Priya Life Science Partners with Fleming for the 9th Annual Corporate Compliance & Transparency in Life Sciences Summit in Zurich Ireland Has the Capital and the Lessons: Digital Project Management Is How They Become Delivery Dunbar Pharma Brings First Plant-Derived Dronabinol API to UK Market Through IPS Pharma Leveraging Priya Life Science as a Data Tracker: The Ultimate Use Case & Career Guide The €100K Reality Check: Why a Six-Figure Pharma Salary in Ireland Feels Different Than in Switzerland or Germany Ireland's €93.8 Billion Non-EU Pharma Export Engine: Trade Data, Destination Markets, and Economic Impact Astellas Expands Its 330 Million Euro Tralee Biopharma Facility with a Second Aseptic Filling Line to Double Drug-Product Capacity Xeolas Pharmaceuticals Opens 158,000 Sq Ft State-of-the-Art Baldoyle Facility to Scale Specialty Medicine Manufacturing Priya Life Science Partners with Fleming for the 9th Annual Corporate Compliance & Transparency in Life Sciences Summit in Zurich Ireland Has the Capital and the Lessons: Digital Project Management Is How They Become Delivery Dunbar Pharma Brings First Plant-Derived Dronabinol API to UK Market Through IPS Pharma Leveraging Priya Life Science as a Data Tracker: The Ultimate Use Case & Career Guide The €100K Reality Check: Why a Six-Figure Pharma Salary in Ireland Feels Different Than in Switzerland or Germany Ireland's €93.8 Billion Non-EU Pharma Export Engine: Trade Data, Destination Markets, and Economic Impact
Recruiting Phase 2/3

Effect of Magnesium Sulphate Pretreatment in Pediatric Abdominal Surgery

NCT05736744 · tracked via the Priya Life Science Egypt tracker
Phase
Phase 2/3
Started
2023-06-20
Last updated
2025-01-20

Condition(s) studied

Muscle Relaxation

Investigational drug(s) / intervention(s)

MgSO4 →Cis-Atracurium

MgSO4: The patients will be pretreated with magnesium sulphate infusion (30 mg kg-1, total volume 100 ml, infusion rate 5 ml min-1) 20 min. before induction of anesthesia.

Cis-Atracurium: Cis-Atracurium will be administered at 0.1-0.15 mg/kg IV bolus for intubation and maintenance at a dose of 0.03 mg/kg iv on fixed intervals.

Study summary

In this study, the investigators will compare the effect of magnesium sulphate pretreatment on the onset and duration of intense and deep neuromuscular Block of rocuronium versus Cis-Atracurium and on the period of no response to nerve stimulation in children undergoing elective open abdominal surgeries.

Eligibility

Sex
ALL
Min age
2 Years
Max age
12 Years
Healthy volunteers
No
Inclusion Criteria: 1. Age group 2-12 years old 2. Both genders 3. Children who will be scheduled to undergo elective laparoscopic surgeries. 4. Patients with American Society of Anesthesiologist physical status classification of 1 or 2- Exclusion Criteria: 1. Patients who are beyond the selected age group. 2. Patients on medications that interfered with muscle activity. 3. Allergy to medications used in this study. 4. Neuro-muscular diseases. 5. Renal or hepatic impairment. 6. Hypermagnesemia (\>2.5 mmol) or hypomagnesemia (\<1.7 mmol). 7. Parental refusal to participate in the study

Primary outcome measure(s)

  • The time of no response to nerve stimulation (seconds) — Intraoperative
    Neuromuscular monitoring will be performed using acceleromyography with the TOF-Watch SX (Organon Ireland Ltd, Dublin, Ireland). Period of no response will be defined as the time period with no response to TOF stimulation (intense and deep NMB).

Trial sites (2)

FacilityCityRegionStatus
Pediatric hospital, faculty of medicine, Assiut university Asyut Assiut Governorate Recruiting
Pediatric hospital Asyut Assiut Governorate Recruiting
Official registry record

This page summarises publicly available registry data for informational purposes — not medical advice. Eligibility is determined by each study team; patients should discuss participation with their clinician.

View NCT05736744 on ClinicalTrials.gov ↗ ← All trials in Egypt